CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
IPO Year:
Exchange: NYSE
Website: CoreSite.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2024 | $275.00 → $245.00 | Buy → Neutral | BofA Securities |
| 2/26/2024 | $261.00 | Outperform | Leerink Partners |
| 1/3/2024 | $242.00 | Overweight | Barclays |
| 12/14/2023 | $213.00 | Equal Weight | Wells Fargo |
| 12/14/2021 | $162.00 → $170.00 | Buy → Neutral | Citigroup |
| 11/26/2021 | $136.00 → $170.00 | Sector Perform | RBC Capital |
| 11/16/2021 | Underweight → Equal-Weight | Barclays | |
| 11/16/2021 | $158.00 → $170.00 | Outperform → Neutral | Credit Suisse |
| 11/16/2021 | Outperform → Market Perform | Raymond James | |
| 10/29/2021 | $149.00 → $153.00 | Outperform | Raymond James |
Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex
The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
SC 13G/A - Cencora, Inc. (0001140859) (Subject)
SC 13D/A - Cencora, Inc. (0001140859) (Subject)
SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)
SC 13G - CoreSite Realty Corp (0001490892) (Subject)
SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)
4 - Cencora, Inc. (0001140859) (Issuer)
Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $3.34 Revenue of $294.0 Billion for Fiscal Year 2024, a 12.1 Percent Year-Over-Year Increase Fiscal Year 2024 GAAP Diluted EPS of $7.53 and Adjusted Diluted EPS of $13.76 Company increases its quarterly dividend by 8 percent Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earni
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2024. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the
Revenue of $74.2 billion for the Third Quarter, a 10.9 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.42 and Adjusted Diluted EPS of $3.34 Adjusted Diluted EPS Guidance Range Raised to $13.55 to $13.65 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.42 for the third quarter of fiscal 2024 compared to $2.35 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items desc
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer Robert P. Mauch, Executive Vice President & Chief Operating Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10
Revenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80 Adjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 1, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer Robert P. Mauch, Executive Vice President & Chief Operating Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 min
Revenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28 Adjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on January 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.
Revenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86 Revenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase Fiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99 Cencora, Inc. (NYSE:COR), formerly AmerisourceBergen Corporation, today reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. Revenue increased 9.9 percent to $262.2 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per shar
Cencora, Inc. (NYSE:COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.06% on an annualized basis producing an average annual return of 21.25%. Currently, Cencora has a market capitalization of $44.28 billion. Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $264.37 today based on a price of $224.84 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
AbbVie Inc (NYSE:ABBV) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the confidentiality of attorney communications. The pharmaceutical company is seeking to overturn a decision by the 3rd U.S. Circuit Court of Appeals, stating that filing a sham patent-infringement lawsuit could override attorney-client privilege. The case stems from allegations in the Philadelphia federal court where drug wholesalers, including Cencora Inc (NYSE:COR) (formerly AmerisourceBergen) and McKesson Corporation (NYSE:MCK), claim they were overcharged for the testosterone replacement drug AndroGel. Also Read: AbbVie’s Parkinson’s Disease
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 6.78% on an annualized basis producing an average annual return of 19.86%. Currently, Cencora has a market capitalization of $43.81 billion. Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $247.56 today based on a price of $222.47 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Cencora (NYSE:COR) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $279.25, with a high estimate of $285.00 and a low estimate of $275.00. This upward trend is apparent,
Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $280 to $285.
Cencora's (NYSE:COR) short percent of float has risen 7.85% since its last report. The company recently reported that it has 9.40 million shares sold short, which is 6.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.73 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impo
Leerink Partners analyst Michael Cherny maintains Cencora (NYSE:COR) with a Outperform and maintains $275 price target.
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 9.87% on an annualized basis producing an average annual return of 23.14%. Currently, Cencora has a market capitalization of $46.22 billion. Buying $1000 In COR: If an investor had bought $1000 of COR stock 5 years ago, it would be worth $2,800.32 today based on a price of $234.70 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PHR PUT TRADE NEUTRAL 06/21/24 $20.00 $570.0K 3.2K 3.1K LLY CALL SWEEP BEARISH 06/07/24 $850.00 $87.7
BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously
Leerink Partners initiated coverage of Cencora with a rating of Outperform and set a new price target of $261.00
Barclays initiated coverage of Cencora with a rating of Overweight and set a new price target of $242.00
Wells Fargo initiated coverage of Cencora with a rating of Equal Weight and set a new price target of $213.00
Citigroup downgraded CoreSite Realty from Buy to Neutral and set a new price target of $170.00 from $162.00 previously
RBC Capital reiterated coverage of CoreSite Realty with a rating of Sector Perform and set a new price target of $170.00 from $136.00 previously
Barclays upgraded CoreSite Realty from Underweight to Equal-Weight
Credit Suisse downgraded CoreSite Realty from Outperform to Neutral and set a new price target of $170.00 from $158.00 previously
Raymond James downgraded CoreSite Realty from Outperform to Market Perform
Raymond James reiterated coverage of CoreSite Realty with a rating of Outperform and set a new price target of $153.00 from $149.00 previously
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K/A - Cencora, Inc. (0001140859) (Filer)
10-Q - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $3.34 Revenue of $294.0 Billion for Fiscal Year 2024, a 12.1 Percent Year-Over-Year Increase Fiscal Year 2024 GAAP Diluted EPS of $7.53 and Adjusted Diluted EPS of $13.76 Company increases its quarterly dividend by 8 percent Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earni
Cencora, Inc. (NYSE:COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America ("RCA"), a leading management services organization (MSO) of retina specialists, from Webster Equity Partners. "The acquisition of RCA will allow Cencora to broaden our relationships with community providers in a high growth segment and build on our leadership in specialty," said Bob Mauch, President & CEO of Cencora. "With a compelling value proposition for physicians, an impressive leadership team and strong clinical research capabilities, RCA is well-positioned at the forefront of retinal care. We intend to use our leading operational infrastructure to help R
Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2024. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the
Frazier Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, is pleased to announce that Willis Chandler has joined the firm's Growth Buyout team as an Executive in Residence. Mr. Chandler will work alongside the firm to develop and execute investment strategies focused on pharma and pharmacy services. In this role, he will focus on the sourcing, diligence, and leadership of a new platform investment for Frazier. "The secular growth in pharma and pharmacy services has been an area of focus for Frazier for several years, and we are thrilled to welcome an industry veteran like Willis to our team," said Nathan Every, General Partner at Frazier. "We are co
Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Frank Clyburn as a new independent director, effective October 1, 2024. With the election of Mr. Clyburn, the Board of Directors will increase to thirteen members. "Cencora's Board of Directors is pleased to welcome Mr. Clyburn as a director. His many years of executive experience, including within the pharmaceutical industry, will be an asset to the company as we continue to focus on long-term, sustainable growth," said Mark Durcan, Lead Independent Director. "Frank is a tenured executive leader who will bring valuable insights and perspectives to his role as a member of our Board," said Steven H. Collis,
Cencora, Inc. (NYSE:COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $250 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora's share repurchase program and the repurchased shares will be held in treasury. About Cencora Cencora is a leading global pharmaceutical solutions organization centered on improvin
Transaction Highlights Walgreens Boots Alliance announces sale of all remaining unencumbered shares of Cencora, Inc. for proceeds of approximately $1.1 billion $818 million sold pursuant to Rule 144 along with a concurrent share repurchase by Cencora of $250 million Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes No change to ongoing collaboration and long-term strategic partnership Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that it has sold all of its remaining unencumbered shares of Cencora, Inc. (NYSE:COR) common stock pursuant to Rule 144 for proceeds of $818 million and, subject to the completio
Revenue of $74.2 billion for the Third Quarter, a 10.9 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.42 and Adjusted Diluted EPS of $3.34 Adjusted Diluted EPS Guidance Range Raised to $13.55 to $13.65 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.42 for the third quarter of fiscal 2024 compared to $2.35 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items desc
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMDInitial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025Strategic partnership with Cencora (formerly AmerisourceBergen) to support the planned commercial launches of LYTENAVA in UK and EU ISELIN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that the United